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Abstract
Chemical probes are powerful reagents with increasing impacts on biomedical research. However, 
probes of poor quality or that are used incorrectly generate misleading results. To help address 
these shortcomings, we will create a community-driven wiki resource to improve quality and 
convey current best practice.
About a decade ago, academia substantially increased its efforts in chemical biology and 
drug discovery. These efforts arose in part because of the availability of large numbers of 
uncharacterized potential drug targets emerging from genome sequencing efforts, from the 
development and commoditization of new screening technologies and from the possibility of 
inventing new medicines. Some of these efforts, perhaps in appreciation of the complexity 
and capriciousness of drug discovery, set out a more measured objective: to generate small-
molecule tools (chemical probes) to help elucidate the roles of the targeted proteins in 
healthy and diseased cells and tissues.
Over the past decade, we have learned some important lessons from these forays into 
chemical biology. First, chemical biology has had a major impact on our understanding of 
human biology and the treatment of human disease. New chemical biology technologies, 
such as the cellular thermal shift assay for assessing direct target engagement in cells1 and 
click chemistry as a means for bioorthogonal functionalization2, are increasingly used in the 
broader scientific community. High-quality chemical probes have served both as powerful 
research tools and as seeds to spur the development of new medicines (Table 1).
Second, chemical reagents, akin to any other protein-targeted reagent, are only useful if they 
are potent, have known selectivity and have a proven mechanism of action. During the past 
decade, we have gained a greater appreciation that probes of this quality are difficult to 
produce and require substantial resources, commitment and skills. We learned that many of 
the chemical probes in use today had initially been characterized inadequately and have 
since been proven to be nonselective or associated with poor characteristics such as the 
presence of reactive functionality that can interfere with common assay features3 (Table 2). 
The continued use of these probes poses a major problem: tens of thousands of publications 
each year use them to generate research of suspect conclusions, at great cost to the taxpayer 
and other funders, to scientific careers and to the reliability of the scientific literature.
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Third, attempts by experts to disseminate accurate and reliable information to the research 
community regarding both well-characterized and poorly characterized chemical probes do 
not seem to be having sufficient impact. Despite a large number of outstanding reviews on 
the aspirational properties of high-quality probes4–6, excellent papers describing frequently 
occurring artifacts in chemical screening and chemical biology3,7 and countless ‘case-by-
case’ papers describing the serious deficiencies of specific chemical probes, nonselective 
and/or poorly characterized compounds continue to be widely used. Thus, the evidence 
suggests that the literature is an ineffective vehicle to provide guidance to the community 
about the quality of new chemical probes or to reduce the use of low-quality chemical 
probes. We argue that a complementary approach is needed.
In this Commentary, we will first, for clarity, provide a working definition of a ‘chemical 
probe’ and then, for perspective, highlight some selected examples of high-quality chemical 
probes (those that are currently believed to be) and probes of lesser value. We will then 
describe our plans to create a web-based resource annotated by the chemical biology 
community comprising the most appropriate chemical probe (or probes) for a given protein 
target. This site, which we have named the Chemical Probes Portal, will be available to 
scientists, reviewers and editors to aid in their experiments and deliberations.
What is a chemical probe?
A chemical probe is simply a reagent—a selective small-molecule modulator of a protein's 
function that allows the user to ask mechanistic and phenotypic questions about its 
molecular target in biochemical, cell-based or animal studies. Chemical probes have proven 
to be very impactful not only because they are complementary to genetic approaches, such 
as CRISPR and RNAi8, but also because they have unique advantages. They can rapidly and 
reversibly inhibit a protein or a protein domain in cells or animals, be used in almost any cell 
type and reveal temporal features of target inhibition. When coupled with RNAi, they can 
distinguish between effects due to scaffolding and effects due to inhibition of catalytic or 
protein-interaction activity. In this way, chemical probes can be quite effective at 
invalidating drug targets9. Multiple chemical probes can also be used in synthetic lethal 
screens to investigate the connectivity between distinct pathways. Finally, and importantly, 
the results obtained with chemical probes are more relevant for translational studies as they 
are more likely to mimic the pharmacology realized when a therapeutic small-molecule drug 
is used.
Only high-quality chemical probes generate meaningful biological data. Quality is a difficult 
parameter to quantify, but excellent guides to the properties required in useful chemical 
probes have been put forth by the expert community5,6. As a working example, within the 
Structural Genomics Consortium (http://www.thesgc.org/), a large collaboration of academic 
and industry medicinal chemists and chemical biologists, probes for epigenetics targets are 
required minimally to have in vitro potency at the target protein of <100 nM, possess >30-
fold selectivity relative to other sequence-related proteins of the same target family, be 
profiled against an ‘industry standard’ selection of pharmacologically relevant off-targets 
(for example, http://www.eurofins.com/pharma-services/pharma-discovery-services/
services/in-vitro-pharmacology.aspx) and against large protein families of relevance to drug 
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discovery and, finally, have demonstrated on-target effects in cells at <1 μM. The 
consortium has strongly encouraged and now requires that the chemical probe be 
accompanied by an inactive close analog of the compound to serve as a negative control. 
Chemical probes for other protein targets or for use in animal models would require 
different criteria as appropriate, but all should go through similar profiling cascades.
Providing one chemical probe for a given protein is also insufficient. Each protein should be 
targeted by another equally well-characterized ‘orthogonal’ chemical probe having a 
completely different chemical structure which would reduce the probability of having 
common off-targets.
Historically, demonstrating on-target activity in cells, and especially in animal models, has 
proven very challenging, particularly for those proteins with no known cellular function. 
Although this task still remains a challenge, chemical biologists can now tackle the problem 
with any of a suite of genetic10, chemical proteomic and biophysical assays11 and ideally 
using a combination of orthogonal methods. The use of molecular genetics to map or 
engineer drug resistance is also a powerful way to link the target, the chemical probe and the 
bioactivity.
In summary, for any given protein, the ideal scenario would be to have two structurally 
distinct chemical probes, each with singular activity and exquisite selectivity, as well as two 
inactive derivatives. However, this aim is often neither realistic nor always necessary. 
Indeed, for each chemical probe, it is only reasonable to expect that the most comprehensive 
analysis possible is made available when the probe is generated, that the counter-screening 
data are made available and that probes are subjected to ongoing and openly shared 
characterization as new technologies and screening panels emerge. In some instances, these 
follow-on studies might highlight serious deficiencies that reduce or eliminate the utility of 
the probe in certain settings or experimental systems, or set the stage for medicinal 
chemistry efforts to produce more potent or selective second-generation probes. Of course, 
first-generation probes with known off-target activities might still be useful provided that 
the off-target activities are judged to be irrelevant to the experiment at hand.
It is also important to understand that small-molecule drugs and chemical probes can be very 
different in their characteristics and their purposes (Fig. 1). For example, a drug need not 
have a selective activity profile, and indeed many medicines manifest their clinical effects 
through polypharmacology. In turn, chemical probes do not need to meet the same 
requirements as a successful medicine, such as good pharmacodynamics and oral 
bioavailability, but they must exhibit high potency, selectivity and on-target action to be 
useful probes of biological questions.
High quality means high impact
Chemical probes have had a major impact in enabling and accelerating discoveries along the 
path to pioneer medicines (Table 1). They have helped to improve our understanding of 
targets and pathways and have created opportunities for proprietary drug discovery efforts to 
an extent that would not have been possible otherwise (Fig. 2a).
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For example, the release of chemical probes for several orphan nuclear receptors led to a 
large increase in drug discovery efforts in this target family. One example is the liver X 
receptor (LXR), which was the target of the agonist GW683965 (Table 1 and Fig. 2b). This 
compound was optimized by iterative medicinal chemistry both for cell potency 
(submicromolar half-maximum effective concentration) and oral bioavailability in mice. In 
conjunction with the structurally distinct LXR agonist T0901317, these compounds made an 
excellent toolset to elucidate LXR biology and to uncover its potential as a therapeutic 
target12. On the basis of these data, the research community produced data suggesting the 
LXRs as potential therapeutic targets in inflammation, atherosclerosis and Alzheimer's 
disease, and several LXR agonists have been progressed for evaluation in humans13.
The BET family bromodomain probes (+)-JQ1, I-BET and PFI-1 constitute another example 
of the impact made by quality chemical probes (Table 1 and Fig. 2c)4. The availability of 
these compounds, accompanied by structurally related inactive negative control compounds, 
enabled the research community to interrogate BET family function in diverse areas such as 
oncology, inflammation, virology and male contraception as well as identify several 
opportunities for drug discovery14. As a specific consequence of openly publishing this 
work and making the tools available for independent validation, several established 
pharmaceutical companies and start-up companies have initiated discovery and clinical 
programs targeting BET proteins only a few years after the initial publication of the 
chemical probes15.
More generally, evidence presented elsewhere16 demonstrates that the availability of a high-
quality chemical probe (or probes) for a target greatly stimulates research activity on that 
protein. Indeed, bibliometric evidence suggests that chemical probes comprise the most 
impactful of all classes of biomedical reagents, as judged by citations and usage16. 
Unfortunately, the impact of chemical probes also extends to those probes of lesser quality.
Caveat emptor
In the previous section, we highlighted some examples of well-characterized chemical 
probes and their impact on scientific understanding and translational medicine. 
Unfortunately, most chemical inhibitors are not characterized appropriately or have outdated 
characterization. As a result, they may have major off-target properties, and their use can 
contribute to misleading or incorrect conclusions.
Another set of compounds in widespread use (Table 2) can deregulate biological systems 
nonspecifically, for example, by affecting the redox state, by forming covalent or 
irreversible adducts with large numbers of proteins, or by forming aggregates3,7; these 
compounds are frequent hits in phenotypic screens. To the experienced chemist, these 
classes of compounds are well known as molecules either to avoid if possible or to be 
treated very cautiously, yet they are used profligately in the literature. A lamentable example 
is BSI-201 (iniparib; Fig. 3), which was developed and advertised as a PARP inhibitor, used 
in thousands of publications and progressed to phase 3 clinical trials, where it failed, and 
was only later shown to modify cysteine-containing proteins nonspecifically17.
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In the following three sections, we highlight a few of the many egregious examples, 
selecting from different areas of cell biology.
Cellular signaling
The discoveries that protein kinases could be inhibited weakly by 
isoquinolinesulfonamides18 and potently by the bacterial natural product staurosporine at 
nanomolar concentrations19 were true breakthroughs, revealing that protein kinases were 
‘druggable’ in cellular systems and paving the way to the discovery of approximately 30 
approved drugs that target the protein kinase domain20. Staurosporine was initially described 
as an inhibitor of protein kinase C (PKC), but over the following decades, as the molecule 
was characterized more fully and ever-larger kinase screening panels became available, it 
became clear that it was not selective for PKC and was instead a pan-kinase inhibitor. At 
some time in this period, the molecule should have been discarded in favor of more selective 
inhibitors that were being discovered. Unfortunately, this did not happen.
The misuse of many other early kinase inhibitors continues to plague the literature. For 
instance, LY294002 was originally described in 1994 as a selective inhibitor of PI3 kinase21 
and remains advertised as such by nearly all vendors. Yet by 2005, it was already clear that 
the compound inhibited many other proteins at the concentrations used to inhibit PI3 
kinase22. In the meantime, a large number of more selective and more well-characterized 
PI3 kinase inhibitors have become available. The availability of these new inhibitors 
certainly obviated the need for LY294002 as a chemical probe, and it should be discarded as 
a selective research tool. Yet a search of Google Scholar in 2014–2015 alone for ‘LY294002 
and PI3 kinase’ returned ∼1,100 documents.
Dorsomorphin is a chemical probe that was first published as a nanomolar inhibitor of TGF-
β signaling and is advertised and used as such23. It was also published as a nanomolar 
inhibitor of AMPK signaling and is advertised and used as such24. In 2014–2015, a search 
of Google Scholar retrieved ∼300 documents using dorsomorphin as a probe of either TGF-
β receptor kinases or AMPK. Which of these activities is responsible for the observed 
biological effects? Perhaps neither. There are at least ten other kinases that are more potently 
inhibited by dorsomorphin than either AMPK or TGF-β receptor kinases25.
A brief review of the protein kinase literature reveals that these are not isolated cases; many 
nonselective and insufficiently characterized inhibitors continue to be used as tools to 
connect specific kinases to biological effects.
Epigenetics
In 1986, DZNep was published as a picomolar inhibitor of S-adenosyl homocysteine (SAH) 
hydrolase26, a key enzyme involved in the biosynthetic pathway of S-adenosyl methionine, 
the cofactor of nearly all cellular methyltransferases. In 2007, when used at a concentration 
a million times higher than that required to inhibit SAH hydrolase in vitro, DZNep was 
reported to reduce methylation of histones, including H3K27, the target of the EZH2 
methyltransferase, ostensibly by downregulating expression of the EZH2 
methyltransferase27. Subsequent publications using DZNep have erroneously implied and 
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interpreted data as though DZNep is a catalytic inhibitor of EZH2. A Google Scholar search 
for ‘DZNep and EZH2’ publications in the past year returned ∼250 documents. A search for 
EZH2 together with the higher-quality inhibitors EPZ005687, EPZ-6438, GSK343 or 
GSK126 returned ∼400 documents over the same period.
The natural product chaetocin contains a pair of disulfide bonds, a substructure that can 
confound assays through nonspecific redox behavior, covalent modification or both28. 
Chaetocin was reported in 2005 to be a selective inhibitor of the Drosophila histone 
methyltransferase SU(VAR)3-9 (ref. 28). In the intervening years, the community realized 
that this compound indeed had activity on many other proteins, and in 2013 chaetocin was 
shown to form covalent adducts with numerous proteins, most likely explaining its 
promiscuity29,30 and confirming its lack of utility as a valuable chemical probe. 
Nevertheless, a Google Scholar search for ‘chaetocin and histone’ returned ∼100 documents 
since 2014.
Apoptosis
The relevance of apoptosis as a target for therapy is being tested through the use of 
ABT-199, also known as GDC-0199 (venetoclax, a nanomolar inhibitor of the BH3–Bcl-2 
interaction that is in phase 3 clinical trials in a variety of cancers31). ABT-263 and 
ABT-737, earlier inhibitors of Bcl-2 family proteins that satisfy all of the criteria of high-
quality probes, are triumphs of chemical biology and modern drug discovery. They are 
rationally designed potent and selective protein-protein interaction inhibitors whose 
mechanisms of action have conclusively been shown to be due to inhibition of the relevant 
target in cells.
Other reported bioactive inhibitors of the BH3–Bcl-2 interaction, including obatoclax, 
chelerythrine, EM20-25, gossypol and apogossypol, are inadequate as probes. Indeed, since 
2009, we have known that none of these agents exert their biological effects through Bcl-2 
alone and perhaps not through Bcl-2 at all32, and many of these inhibitors contain structural 
motifs that would raise concern with any experienced medicinal chemist3. Nevertheless, a 
Google Scholar search for any of these compounds and Bcl in 2014 or 2015 returned about 
as many documents as did a search for ‘ABT-737 and Bcl’.
The sins of the past
On the basis of these examples, our collective experience over the past decade or so 
highlights four factors that contribute to the continued use of nonselective chemical probes.
First, it is difficult for the research community to keep abreast of recent developments and to 
remain well informed about the most appropriate probe for a given target. Chemical probe 
experts, including the authors here, are routinely queried as to whether there is a high-
quality probe available for a given target or for advice on which probe to use. In the absence 
of expert advice, and with no other recourse available, the selection of a probe compound 
seems to be guided by precedent and availability rather than appropriateness or quality.
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Second, some of the high-quality probes are not commercially available and are beyond the 
reach of scientists who may not have access to synthetic chemistry expertise. On other rare 
occasions, commercially available probes are of insufficient purity, stability or quality; 
sometimes what is in the bottle is not what is printed on the label33.
Third, even if high-quality probes are available, they are sometimes used at concentrations at 
which they become nonselective and render the biological insights derived from these 
experiments uninterpretable.
Fourth, dissemination of these insights and provision of guidelines via the peer-reviewed 
literature has clearly proven inadequate to improve the situation. As shown above, recent 
papers (and grant applications) making mechanistic conclusions based on the use of 
nonselective probes continue to be published by the thousands despite clear and convincing 
publications that point out their flaws. The financial implications are especially important to 
note as these studies are often supported by public funds.
Toward a rosier future
“Discontent is the first necessity of progress.”
—Thomas Edison
The well-documented use of suboptimal probes and the misuse of high-quality probes 
suggest that alternative mechanisms to disseminate information are necessary. We believe 
that an expert community-driven wiki-like site is one possible solution and one that we will 
implement (http://www.chemicalprobes.org/). In this resource, which we call the Chemical 
Probes Portal, we plan to crowdsource medicinal chemistry and pharmacology expertise to 
answer the most common questions we receive: Is there a probe for my target protein? 
Which ones should I use? How should I use this probe properly? Is this probe suitable for 
use in animal models?
In this resource we will suggest the best available chemical probe (or probes) for a protein 
target and ensure that each probe is accompanied by the most current available information 
on activity and selectivity, including information about the best available compounds to use 
as controls. We also expect to provide experimental guidance on how to best use the probes. 
For those proteins that have suboptimal but still useful probe compounds available, we will 
describe both their benefits and limitations, along with specific guidance on their use. 
Ideally, the scientific community will reciprocate by adding its feedback and by placing any 
new data into any of the outstanding chemical biology databases (PubChem, ChEMBL and 
so on).
The authors will oversee the generation and maintenance of this resource to begin with, but 
ultimately its success depends on community input (‘wikification’) and use. This resource 
will need to be supported and used by academic and industrial researchers, publishers, 
funders and investors, groups that share a common interest in increasing the reliability of the 
published literature and the robustness of target validation. As with many other wiki 
resources, the chemical probe validation information from the community would be curated 
by specialists with expertise about the probes in question.
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The Chemical Probes Portal will also help address the challenges faced by peer reviewers in 
evaluating grants or manuscripts that describe or make use of small-molecule tools. 
However, our resource may be insufficient or incomplete and cannot be used to judge new 
chemical probes, and thus we also recommend that reviewers and editors provide a checklist 
of areas to address in the preparation and review of manuscripts where chemical probes are 
generated and used to drive key biological conclusions (Box 1). Additionally, because the 
communities that generate chemical probes and those that use them are often disconnected, 
we strongly believe that no paper where a chemical probe is reported or used should be 
reviewed without including someone who is deeply familiar with proper usage of chemical 
probes, especially when a tool is used in animal models where pharmacokinetics and 
metabolism will have dominant roles. We also encourage vendors to provide selectivity and 
metabolic stability profiles and realistic guidelines indicating relevant concentrations for cell 
culture or animal studies. Where available, vendors are also encouraged to offer the inactive 
analog of the probe for use as a negative control.
Chemical probes can be powerful research tools in studies of protein function. The resource 
that we outline here will increase the proper use of the best available probe compounds and 
will reduce the use of inadequate probes. If successful, it will help to increase understanding 
of fundamental biology and identify new therapeutic opportunities for the discovery of 
medicines.
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Checklist for chemical probe–based experiments
As authors, editors and referees evaluate studies containing experiments using chemical 
probes, they should ask themselves the following questions:
• Is the potency and selectivity of the probe suitable for drawing the conclusions 
of the experiment?
• Is the probe used at an appropriate concentration relative to its XC50 (the 
concentration at which half-maximal activity change is observed, encompassing 
both IC50 and EC50) values at the primary protein target and any known off-
target proteins?
• Is evidence presented that the chemical probe is engaging its target in cells?
• Are the appropriate control compounds used? Specifically, does the study 
include a structurally related inactive compound for the same target? Does it 
include parallel data with a structurally unrelated chemical probe?
• Is the source and purity of the compound documented?
• Is the chemical structure of the probe compound (including stereoisomerism, if 
applicable) reported?
• If planning in vivo experiments, does the probe have appropriate 
pharmacokinetics and pharmacology to be utilized in animal models?
Arrowsmith et al. Page 12














Different purposes and requirements for chemical probes and drugs. IP, intellectual 
property; MoA, mechanism of action; MW, molecular weight.
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Chemical probes are valuable research tools. (a) Open access to quality chemical probes can 
inform initial target selection. (b,c) Examples of chemical probes for the LXRs (b) and BET 
family bromodomains (c).
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Structures for selected compounds.
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Table 1
Examples of high-impact chemical probes
Probe Target Mode of action
(+)-JQ1, I-BET, PFI-1 (ref. 4) BET family bromodomains Inhibitor
Rapamycin mTOR Allosteric inhibitor
GW683965 (ref. 12) LXRα and LXRβ Agonist
PF-04457845 (ref. 34) Fatty acid amide hydrolase Irreversible inhibitor
GNF-5 (ref. 35) Bcr-Abl Allosteric inhibitor
Cyclopamine Smoothened Orthosteric inhibitor













Arrowsmith et al. Page 17
Table 2
Examples of widely used low-quality probes
Compound Putative target Problems
Flavones Many, varied Often promiscuous and can be pan-assay interfering (PAINS) compounds
Epigallocatechin-3-gallate DYRK1A Promiscuous PAINS compound
LiCl GSK3β Typically used at high (mM) concentrations; known to inhibit other targets36
WY14643 (ref. 37) PPARα Significant activity difference in human versus murine orthologs of target
Valproicacid38 HDAC Used at concentration regimes (mM) where nonspecific mechanisms are likely
Resveratrol Sirtuin Assay artifact39
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